表紙
市場調查報告書

新型冠狀病毒傳染病(COVID-19)臨床試驗考察 2020年

Global Coronavirus COVID 19 Clinical Trials Insight 2020

出版商 KuicK Research 商品編碼 927164
出版日期 內容資訊 英文 60 Pages
商品交期: 最快1-2個工作天內
價格
新型冠狀病毒傳染病(COVID-19)臨床試驗考察 2020年 Global Coronavirus COVID 19 Clinical Trials Insight 2020
出版日期: 2020年03月01日內容資訊: 英文 60 Pages
簡介

新型冠狀病毒傳染病(COVID-19)於中國爆發,目前已在全球許多國家確認了其感染流行。疫情爆發已經過2個月,但迄今仍未發售有效治療藥物。隨著新型冠狀病毒傳染病(COVID-19)的全球流行,研究機構正聚焦冠狀病毒的有效疫苗開發。

本報告研究全球的新型冠狀病毒傳染病(COVID-19)臨床試驗,彙整按區分的臨床試驗概要、各階段PIPELINE治療藥考察、市場趨勢、市場機會預測、主要企業簡介等情報。

目錄

第1章 全球新型冠狀病毒傳染病(COVID-19)臨床試驗概要

  • 按Phase
  • 按企業
  • 按國家
  • 按藥物分類

第2章 新型冠狀病毒傳染病(COVID-19)研究階段的PIPELINE

  • 大麻二酚濃縮萃取物
  • 冠狀病毒疫苗:Vaxil BioTherapeutics
  • ACE2
  • 小分子治療藥
  • SARS-CoV-2疫苗
  • 冠狀病毒抗體
  • 基因重組疫苗
  • 基因重組次單位疫苗
  • Interferon Alpha
  • AdVac/PERC6冠狀病毒疫苗
  • SARS-CoV-2疫苗:Codagenix
  • 冠狀病毒疫苗:CureVac
  • 冠狀病毒混合疫苗
  • Nanoviricid技術
  • DNA冠狀病毒疫苗
  • 基於FastPharming System的病毒
  • 冠狀病毒中和抗體
  • 抗感染抗體治療藥
  • Angiopoietin-Tie2 信號傳達路徑標靶藥
  • 小分子干擾RNA治療藥
  • INO 4800
  • MVA類病毒顆粒冠狀病毒疫苗
  • 中和抗體治療藥
  • mRNA 1273

第3章 新型冠狀病毒傳染病(COVID-19)臨床前試驗PIPELINE

  • Rintatolimod
  • Matrix-M(Saponin-Based Adjuvant)
  • 不活化冠狀病毒疫苗
  • 線性DNA疫苗

第4章 新型冠狀病毒傳染病(COVID-19)Phase-I臨床試驗PIPELINE

  • ITMN-191

第5章 新型冠狀病毒傳染病(COVID-19)Phase-II臨床試驗PIPELINE

  • ASC 09F

第6章 新型冠狀病毒傳染病(COVID-19)Phase-III臨床試驗PIPELINE

  • GS 5734

第7章 競爭情勢

  • AIM ImmunoTech
  • Ascletis
  • Gilead Sciences
  • iBio Inc
  • Inovio Pharmaceuticals
  • LineaRx
  • Mannin Research
  • Moderna Therapeutics
  • NanoViricides
  • Novavax
  • Q BioMed
  • Sanofi Pasteur
  • Sirnaomics
  • Takis
  • WuXi Biologics
目錄

"Global Coronavirus COVID 19 Clinical Trials Insight 2020" Report Highlight:

  • Number Of Drugs In Clinical Trials: >30 Drugs
  • Majority Of Drugs in Research Phase: > 15 Drugs
  • USA & China Dominating Clinical Trials: >20 Drugs
  • Vaccines Accounts Major Share In Clinical Trials: >10 Vaccines
  • Expected Market Opportunity: > US$ 1 Billion

The research report “Global Coronavirus COVID 19 Clinical Trials Insight 2020” discusses about the recent outbreak of coronavirus that has badly affected the human life globally. The report provides an in-depth analysis about the clinical trials of drugs and therapies for the virus that is going to be covered in the next few years. The multiple aspects that are linked with the virus spread have been discussed elaborately in different sections of the report. In addition to the information that the report is delivering, it is also providing the recent research and development work that is in progress to unmold the epidemic that has caused large number of deaths at regional and global level.

In general the report has been prepared with a view of providing all the clinical parameters associated with the virus therapy research. Starting from a single country, the virus has confirmed its presence in almost each and every country of the world. It has been two months since the outbreak of the corona virus, but till now no such commercial treatment is available in the market. Since the recent outbreak of the virus at the global level, the research fields at all the levels have focused their work on developing a vaccine that will be effective against the mechanism of the coronavirus by which it is escaping all the commercially available vaccines for virus.

On an average, more than 30 clinical trials are getting conducted at the global level, with hundreds of patients enrolled in it. Out of the 30 clinical trials that have been initiated for finding the treatment, only few have cleared the early stages of trial and are on the urge to begin with the Phase III of their clinical trial. The research report regarding the recent epidemic that has taken over all the focus has covered all the current drugs that are in pipeline of getting emerged as the possible treatments for the coronavirus. It is well witnessed by observing the number of coronavirus cases by each passing day that the research that is currently getting performed is at its best. The outbreak of the virus has led advancement in the partnership for the technological support. By observing the number of the patients and the healthcare management all the world, it is expected that the very first therapy against the virus will be launched by next year i.e. 2021.

Table of Contents

1. Global Coronavirus COVID 19 Clinical Trial Overview

  • 1.1. By Phase
  • 1.2. By Company
  • 1.3. By Country
  • 1.4. By Drug Class

2. Research Phase-COVID 2019 Infections Clinical Pipeline

  • 2.1. Cannabidiol Enriched Extract
  • 2.2. Coronavirus Vaccine-Vaxil BioTherapeutics
  • 2.3. ACE2
  • 2.4. Small Molecule Based Therapeutics
  • 2.5. SARS-CoV-2 Vaccine Therapeutics
  • 2.6. Coronavirus Antibodies
  • 2.7. Recombinant Vaccines
  • 2.8. Recombinant Subunit Vaccine
  • 2.9. Interferon Alpha Therapy
  • 2.10. AdVac® and PER.C6® Based Coronavirus Vaccine
  • 2.11. SARS-CoV-2 Vaccine - Codagenix
  • 2.12. Coronavirus Vaccine-CureVac
  • 2.13. Coronavirus Hybrid Vaccines
  • 2.14. Nanoviricide® Technology
  • 2.15. DNA Coronavirus Vaccine
  • 2.16. FastPharming System™ Based Viral
  • 2.17. Coronavirus Neutralising Antibodies
  • 2.18. Anti-Infective Antibody Therapeutics
  • 2.19. Angiopoietin-Tie2 Signaling Targetting
  • 2.20. Small interfering RNA Based Therapeutics
  • 2.21. INO 4800
  • 2.22. Modified Vaccinia Ankara-Virus-Like Particles Coronavirus Vaccine
  • 2.23. Neutralising Antibody Therapeutics
  • 2.24. mRNA 1273

3. Preclinical Phase-COVID 2019 Infections Clinical Pipeline

  • 3.1. Rintatolimod
  • 3.2. Matrix-M™ Saponin-Based Adjuvant
  • 3.3. Inactivated Coronavirus Virus Vaccine
  • 3.4. Linear DNA Based Vaccine

4. Clinical Phase-COVID 2019 Infections Clinical Pipeline

  • 4.1. ITMN-191

5. Phase-II-COVID 2019 Infections Clinical Pipeline

  • 5.1. ASC 09F

6. Phase-III-COVID 2019 Infections Clinical Pipeline

  • 6.1. GS 5734

7. Competitve Landscape

  • 7.1. AIM ImmunoTech
  • 7.2. Ascletis
  • 7.3. Gilead Sciences
  • 7.4. iBio Inc
  • 7.5. Inovio Pharmaceuticals
  • 7.6. LineaRx
  • 7.7. Mannin Research
  • 7.8. Moderna Therapeutics
  • 7.9. NanoViricides
  • 7.10. Novavax
  • 7.11. Q BioMed
  • 7.12. Sanofi Pasteur
  • 7.13. Sirnaomics
  • 7.14. Takis
  • 7.15. WuXi Biologics

List of Figures

  • Figure 1-1: Global-Coronavirus COVID 19 Clinical Trials By Phase (Number), 2020
  • Figure 1-2: Global-Coronavirus COVID 19 Clinical Trials By Phase (%), 2020
  • Figure 1-3: Global-Coronavirus COVID 19 Clinical Trials By Drug Class (Number), 2020
  • Figure 1-4: Global-Coronavirus COVID 19 Clinical Trials By Country (Number), 2020
  • Figure 1-5: Global-Coronavirus COVID 19 Clinical Trials By Drug Class (Number), 2020